Recombinant adeno-associated viruses (rAAVs) are the leading in vivo gene delivery platform, and have been extensively studied in gene therapy targeting various tissues, including the central nervous system (CNS). A single-bolus rAAV injection to the cerebrospinal fluid (CSF) space has been widely used to target the CNS, but it suffers from several drawbacks, such as leakage to peripheral tissues. Here, a protocol is described using an osmotic pump to infuse rAAV slowly into the mouse CSF space. Compared to the single-bolus injection technique, pump infusion can lead to higher CNS transduction and lower transduction in the peripheral tissues.
Get full access to this article
View all access options for this article.
References
1.
FoustKD, NurreE, MontgomeryCL, et al.Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol, 2009; 27:59–65.
2.
DuqueS, JoussemetB, RiviereC, et al.Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther, 2009; 17:1187–1196.
3.
ZhangH, YangB, MuX, et al.Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther, 2011; 19:1440–1448.
4.
GraySJ, MatagneV, BachaboinaL, et al.Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther, 2011; 19:1058–1069.
5.
MendellJR, Al-ZaidyS, ShellR, et al.Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med, 2017; 377:1713–1722.
6.
SnyderBR, GraySJ, QuachET, et al.Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. Hum Gene Ther, 2011; 22:1129–1135.
7.
ElligerSS, ElligerCA, AguilarCP, et al.Elimination of lysosomal storage in brains of MPS VII mice treated by intrathecal administration of an adeno-associated virus vector. Gene Ther, 1999; 6:1175–1178.
8.
PeelAL, ZolotukhinS, SchrimsherGW, et al.Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Ther, 1997; 4:16–24.
9.
WatsonG, BastackyJ, BelichenkoP, et al.Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice. Gene Ther, 2006; 13:917–925.
10.
StorekB, HarderNM, BanckMS, et al.Intrathecal long-term gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in rats. Mol Pain, 2006; 2:4.
11.
StorekB, ReinhardtM, WangC, et al.Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain. Proc Natl Acad Sci U S A, 2008; 105:1055–1060.
12.
IwamotoN, WatanabeA, YamamotoM, et al.Global diffuse distribution in the brain and efficient gene delivery to the dorsal root ganglia by intrathecal injection of adeno-associated viral vector serotype 1. J Gene Med, 2009; 11:498–505.
13.
TowneC, PertinM, BeggahAT, et al.Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery. Mol Pain, 2009; 5:52.
14.
MasonMR, EhlertEM, EggersR, et al.Comparison of AAV serotypes for gene delivery to dorsal root ganglion neurons. Mol Ther, 2010; 18:715–724.
15.
VulchanovaL, SchusterDJ, BelurLR, et al.Differential adeno-associated virus mediated gene transfer to sensory neurons following intrathecal delivery by direct lumbar puncture. Mol Pain, 2010; 6:31.
16.
SchusterDJ, DykstraJA, RiedlMS, et al.Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse. Front Neuroanat, 2014; 8:42.
17.
GuoY, WangD, QiaoT, et al.A single injection of recombinant adeno-associated virus into the lumbar cistern delivers transgene expression throughout the whole spinal cord. Mol Neurobiol, 2016; 53:3235–3248.
18.
BeyK, CironC, DubreilL, et al.Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders. Gene Ther, 2017; 24:325–332.
19.
HordeauxJ, DubreilL, DeniaudJ, et al.Efficient central nervous system AAVrh10-mediated intrathecal gene transfer in adult and neonate rats. Gene Ther, 2015; 22:316–324.
20.
BucherT, ColleMA, WakelingE, et al.scAAV9 intracisternal delivery results in efficient gene transfer to the central nervous system of a feline model of motor neuron disease. Hum Gene Ther, 2013; 24:670–682.
21.
BucherT, DubreilL, ColleMA, et al.Intracisternal delivery of AAV9 results in oligodendrocyte and motor neuron transduction in the whole central nervous system of cats. Gene Ther, 2014; 21:522–528.
22.
GurdaBL, De Guilhem De LatailladeA, BellP, et al.Evaluation of AAV-mediated gene therapy for central nervous system disease in canine mucopolysaccharidosis VII. Mol Ther, 2016; 24:206–216.
23.
HindererC, BellP, KatzN, et al.Evaluation of intrathecal routes of administration for adeno-associated viral vectors in large animals. Hum Gene Ther, 2018; 29:15–24.
24.
FedericiT, TaubJS, BaumGR, et al.Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther, 2012; 19:852–859.
25.
PassiniMA, BuJ, RichardsAM, et al.Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy. Hum Gene Ther, 2014; 25:619–630.
26.
SamaranchL, SalegioEA, San SebastianW, et al.Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther, 2012; 23:382–389.
27.
GraySJ, Nagabhushan KalburgiS, McCownTJ, et al.Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther, 2013; 20:450–459.
28.
SamaranchL, SalegioEA, San SebastianW, et al.Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum Gene Ther, 2013; 24:526–532.
29.
HindererC, BellP, ViteCH, et al.Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna. Mol Ther Methods Clin Dev, 2014; 1:14051.
30.
SamaranchL, San SebastianW, KellsAP, et al.AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Mol Ther, 2014; 22:329–337.
31.
WangH, YangB, QiuL, et al.Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum Mol Genet, 2014; 23:668–681.
32.
DirrenE, AebischerJ, RochatC, et al.SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice. Ann Clin Transl Neurol, 2015; 2:167–184.
33.
SinnettSE, HectorRD, GadallaKKE, et al.Improved MECP2 gene therapy extends the survival of MeCP2-null mice without apparent toxicity after intracisternal delivery. Mol Ther Methods Clin Dev, 2017; 5:106–115.
34.
HaurigotV, MarcoS, RiberaA, et al.Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest, 2013Jul1 [Epub ahead of print]; DOI: 10.1172/JCI66778.
35.
HindererC, BellP, GurdaBL, et al.Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I. Mol Ther, 2014; 22:2018–2027.
36.
HindererC, KatzN, LouboutinJP, et al.Delivery of an adeno-associated virus vector into cerebrospinal fluid attenuates central nervous system disease in mucopolysaccharidosis type II mice. Hum Gene Ther, 2016; 27:906–915.
37.
HordeauxJ, DubreilL, RobveilleC, et al.Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease. Acta Neuropathol Commun, 2017; 5:66.
38.
MeyerK, FerraiuoloL, SchmelzerL, et al.Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose–response study in mice and nonhuman primates. Mol Ther, 2015; 23:477–487.
39.
LiD, LiuC, YangC, et al.Slow intrathecal injection of rAAVrh10 enhances its transduction of spinal cord and therapeutic efficacy in a mutant SOD1 model of ALS. Neuroscience, 2017; 365:192–205.
40.
MurlidharanG, SakamotoK, RaoL, et al.CNS-restricted transduction and CRISPR/Cas9-mediated gene deletion with an engineered AAV vector. Mol Ther Nucleic Acids, 2016; 5:e338.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
